Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak

Cell Death and Disease

Volumn 3, Issue 8, 2012, Pages

  Melarangi, T ^a   Zhuang, J ^a   Lin, K ^a,b   Rockliffe, N ^a   Bosanquet, A G ^c,d   Oates, M ^a   Slupsky, J R ^a   Pettitt, A R ^a,b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c ROYAL UNITED HOSPITAL   (United Kingdom)

^d TEST Laboratories Ltd   (United Kingdom)

Author keywords

Apoptosis; Bcl 2; Bim; Cll; Glucocorticoids

Indexed keywords

BIM PROTEIN; DEXAMETHASONE; FLUDARABINE; GLUCOCORTICOID; HYDROCORTISONE; MESSENGER RNA; METHYLPREDNISOLONE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BCL 2 LIKE PROTEIN 11; BCL-2-LIKE PROTEIN 11; DRUG DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; ONCOPROTEIN; PROTEIN P53; VIDARABINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; FEMALE; HUMAN; IMMUNOPRECIPITATION; MALE; MOLECULAR MECHANICS; PRIORITY JOURNAL; TREATMENT FAILURE; UPREGULATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROTEIN BINDING; RNA INTERFERENCE; TUMOR CELL CULTURE;

AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOPRECIPITATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NF-KAPPA B; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; VIDARABINE;

EID: 84865761572     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.102     Document Type: Article

References (41)

1. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10: 37-50.
2. Thornton PD, Matutes E, Bosanquet AG, Lakhani AK, Grech H, Ropner JE et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003; 82: 759-765. (Pubitemid 38008843)
3. Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008; 22: 2048-2053.
4. Dungarwalla M, Evans SO, Riley U, Catovsky D, Dearden CE, Matutes E. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 2008; 93: 475-476. (Pubitemid 351398657)
5. Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 2009; 23: 1779-1789.
6. Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukaemia and deletion of TP53: Final results of the National Cancer Research Institute CLL206 Trial. J Clin Oncol 2012; 30: 1647-1655.
7. Gross KL, Lu NZ, Cidlowski JA. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol 2009; 300: 7-16.
8. Hala M, Hartmann BL, Bock G, Geley S, Kofler R. Glucocorticoid-receptor- gene defects and resistance to glucocorticoid-induced apoptosis in human leukemic cell lines. Int J Cancer 1996; 68: 663-668. (Pubitemid 26414529)
9. Geley S, Hartmann BL, Hala M, Strasser-Wozak EM, Kapelari K, Kofler R. Resistance to glucocorticoid-induced apoptosis in human T-cell acute lymphoblastic leukemia CEM-C1 cells is due to insufficient glucocorticoid receptor expression. Cancer Res 1996; 56: 5033-5038. (Pubitemid 26374445)
10. Greenstein S, Ghias K, Krett NL, Rosen ST. Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res 2002; 8: 1681-1694. (Pubitemid 34633722)
11. Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 2004; 11(Suppl 1): S45-S55. (Pubitemid 39136798)
12. Wang Z, Malone MH, He H, McColl KS, Distelhorst CW. Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J Biol Chem 2003; 278: 23861-23867. (Pubitemid 36830212)
13. Chauhan D, Auclair D, Robinson EK, Hideshima T, Li G, Podar K et al. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene 2002; 21: 1346-1358. (Pubitemid 34214500)
14. Casale F, Addeo R, D'Angelo V, Indolfi P, Poggi V, Morgera C et al. Determination of the in vivo effects of prednisone on Bcl-2 family protein expression in childhood acute lymphoblastic leukemia. Int J Oncol 2003; 22: 123-128.
15. Chandra J, Gilbreath J, Freireich EJ, Kliche KO, Andreeff M, Keating M et al. Protease activation is required for glucocorticoid-induced apoptosis in chronic lymphocytic leukemic lymphocytes. Blood 1997; 90: 3673-3681. (Pubitemid 27473438)
16. Bellosillo B, Dalmau M, Colomer D, Gil J. Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells. Blood 1997; 89: 3378-3384. (Pubitemid 27229825)
17. Bellosillo B, Villamor N, Lopez-Guillermo A, Marcé S, Bosch F, Campo E et al. Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. Blood 2002; 100: 1810-1816. (Pubitemid 34925161)
18. Iglesias-Serret D, de Frias M, Santidrian AF, Coll-Mulet L, Cosialls AM, Barragán M et al. Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells. Leukemia 2007; 21: 281-287. (Pubitemid 46158121)
19. Soufi M, Kaiser U, Schneider A, Beato M, Westphal HM. The DNA and steroid binding domains of the glucocorticoid receptor are not altered in mononuclear cells of treated CLL patients. Exp Clin Endocrinol Diabetes 1995; 103: 175-183.
20. Shahidi H, Vottero A, Stratakis CA, Taymans SE, Karl M, Longui CA et al. Imbalanced expression of the glucocorticoid receptor isoforms in cultured lymphocytes from a patient with systemic glucocorticoid resistance and chronic lymphocytic leukemia. Biochem Biophys Res Commun 1999; 254: 559-565. (Pubitemid 29290505)
21. Bosanquet AG, Richards SM, Wade R, Else M, Matutes E, Dyer MJ et al. Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing. Br J Haematol 2009; 146: 384-395.
22. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362: 849-852. (Pubitemid 23132162)
23. Carter A, Lin K, Sherrington PD, Pettitt AR. Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia. Br J Haematol 2004; 127: 425-428. (Pubitemid 39536594)
24. Aleskog A, Tobin G, Laurell A, Thunberg U, Lindhagen E, Roos G et al. VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia. Eur J Haematol 2004; 73: 407-411. (Pubitemid 39564363)
25. Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML et al. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 2008; 111: 4681-4689.
26. Neumann M, Naumann M. Beyond IkappaBs: alternative regulation of NF-kappaB activity. FASEB J 2007; 21: 2642-2654. (Pubitemid 47372732)
27. Nelson G, Wilde GJ, Spiller DG, Kennedy SM, Ray DW, Sullivan E et al. NF-kappaB signalling is inhibited by glucocorticoid receptor and STAT6 via distinct mechanisms. J Cell Sci 2003; 116: 2495-2503. (Pubitemid 36790131)
28. Erlacher M, Michalak EM, Kelly PN, Labi V, Niederegger H, Coultas L et al. BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood 2005; 106: 4131-4138. (Pubitemid 41775918)
29. Tan TT, Degenhardt K, Nelson DA, Beaudoin B, Nieves-Neira W, Bouillet P et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005; 7: 227-238. (Pubitemid 40568682)
30. Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB. BH3-only proteins that bind prosurvival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 2001; 15: 1481-1486. (Pubitemid 32552527)
31. Suzuki M, Youle RJ, Tjandra N. Structure of Bax: coregulation of dimer formation and intracellular localisation. Cell 2000; 103: 645-654.
32. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
33. Hsu Y-T, Youle RJ. Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations. J Biol Chem 1998; 273: 10777-10783. (Pubitemid 28227695)
34. Griffiths GJ, Dubrez L, Morgan CP, Jones NA, Whitehouse J, Corfe BM et al. Cell damage-induced conformational changes of the proapoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol 1999; 144: 903-914. (Pubitemid 29238967)
35. Panaretakis T, Pokrovskaja K, Shoshan MC, Grander D. Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. J Biol Chem 2002; 277: 44317-44326. (Pubitemid 36157866)
36. Bachmann PS, Piazza RG, Janes ME, Wong NC, Davies C, Mogavero A et al. Epigenetic silencing of BIM in glucocorticoid poorresponsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood 2010; 116: 3013-3022.
37. Richter-Larrea JA, Robles EF, Fresquet V, Beltran E, Rullan AJ, Agirre X et al. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood 2010; 116: 2531-2542.
38. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002; 2: 183-192. (Pubitemid 41043974)
39. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007; 117: 112-121. (Pubitemid 46048458)
40. Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, Fairlie WD et al. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 2009; 23: 2034-2041.
41. Pettitt AR, Sherrington PD, Cawley JC. Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues. Cancer Res 2000; 60: 4187-4193. (Pubitemid 30636603)